Mereo BioPharma Group (MREO) Operating Margin: 2023-2025
Historic Operating Margin for Mereo BioPharma Group (MREO) over the last 3 years, with Sep 2025 value amounting to -3,681.99%.
- Mereo BioPharma Group's Operating Margin fell 633723.00% to -3,681.99% in Q3 2025 from the same period last year, while for Sep 2025 it was 15,306.51%, marking a year-over-year increase of 66888985.00%. This contributed to the annual value of 3,457.23% for FY2024, which is 374139.00% up from last year.
- Mereo BioPharma Group's Operating Margin amounted to -3,681.99% in Q3 2025, which was down 108.42% from 43,745.83% recorded in Q2 2025.
- In the past 5 years, Mereo BioPharma Group's Operating Margin ranged from a high of 43,745.83% in Q2 2025 and a low of -3,681.99% during Q3 2025.
- Over the past 3 years, Mereo BioPharma Group's median Operating Margin value was 2,655.24% (recorded in 2024), while the average stood at 5,643.67%.
- Within the past 5 years, the most significant YoY rise in Mereo BioPharma Group's Operating Margin was 3,987,453bps (2025), while the steepest drop was 633,723bps (2025).
- Mereo BioPharma Group's Operating Margin (Quarterly) stood at -712.80% in 2023, then soared by 478,613bps to 4,073.33% in 2024, then slumped by 633,723bps to -3,681.99% in 2025.
- Its Operating Margin stands at -3,681.99% for Q3 2025, versus 43,745.83% for Q2 2025 and 6,223.33% for Q1 2025.